Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B

NCT01906580 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT01906580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01906580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B
Lead sponsor
Beijing 302 Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
July 31, 2011
Completion date
July 31, 2016
Enrollment
105 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b